Liver and WAT transcriptomic analyses To examine downstream systemic effects of genetic and pharmacologic manipulations, transcriptomic analysis was conducted on inguinal WAT (Fig
Recent research and observational reports have highlighted: Self-reported reductions in alcohol cravings among some individuals taking GLP-1 medications Decreases in alcohol consumption noted in limited human studies Reduced alcohol-seeking behavior observed in animal models Researchers have proposed several mechanisms that may help explain these findings, including: Modulation of dopamine signaling within reward-related brain pathways Reduced reinforcement or reward response associated with alcohol intake Altered motivation or craving intensity related to substance use It is important to note that existing studies have significant limitations, such as: Small sample sizes and short study durations Reliance on self-reported alcohol use rather than objective measures A lack of randomized, controlled clinical trials Key context to keep in mind: GLP-1 medications are not approved for the treatment of alcohol use disorder Reported effects vary widely between individuals Current evidence is insufficient to establish causation or clinical benefit Research in this area is ongoing, and no definitive conclusions can be drawn at this time
10.1083/jcb.127.6.1617 96 GarciaJ
One possible justification is that rapid weight loss or reduced calorie intake could temporarily disrupt hormone balance
In addition to their well-known anti-inflammatory effects, EPA and DHA may also have anti-arrhythmic properties, and have been found in multiple studies to benefit heart disease patients by improving lipid levels, lowering blood pressure, and reducing the risk of sudden death (Colussi 2018
When used together, Sculptra and Restylane create a thoughtful, layered approach that is especially well suited for treating facial volume loss after significant weight loss
